Biodesix (Broomfiled, CO) a commercial-stage molecular diagnostics company focused on proteomic-based diagnostics, closed the first tranche of a $10M Series B financing. The company is enabling personalized health care via their mass spectrometry-based molecular profiling proprietary platform technology, ProTS®, to discover and validate diagnostic tests for the improvement of patient outcomes.
Biodesix' first product, VeriStrat®, a pretreatment serum proteomic test for patients with advanced non-small cell lung cancer is now commercially available for physicians to help guide their treatment of patients (view the demo [HERE]). The test identifies patients who are likely to have good or poor outcomes after treatment with EGFR-TKIs. Samples are processed in Biodesix' CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment. VeriStrat® has been validated in clinical studies with over 1000 patients, and the Company is engaging in additional studies to further validate the test and to explore the clinical utility of VeriStrat® in other solid epithelial tumors and with other EGFR inhibitors.